nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.01.2010 | Original Article

Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat

verfasst von: Tanushree Das, Falguni Patra, Biswajit Mukherjee

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In ras-mediated signal transduction pathway, c-raf.1 is believed to have predominant oncogenic potential and has been found to be highly expressed in certain human and animal malignancies including hepatocellular carcinoma. In the present study, anticancer efficacy of antisense c-raf.1 oligomer on the inhibition of c-raf.1 mRNA overexpression during hepatocarcinogenesis was determined.

Methods

Initially antiproliferating effect of the antisense oligomers was studied in vitro by measuring the rate of tritiated thymidine incorporation into DNA in rat hepatocellular carcinoma cells in culture medium. Based on the findings, the antisense treatment was carried out in rat hepatocarcinogenesis model-initiated with diethylnitrosamine and promoted using 2-acetylaminoflourene. Different drug-metabolizing enzymes, lipid peroxidation, liver morphology and histopathological studies along with c-raf.1 gene expression by in situ hybridization were performed.

Results

c-raf.1 antisense oligomers exhibited an inhibitory effect (~68%) on cancer cell proliferation in vitro. Gross and microscopic examination of liver showed fewer (29%) and smaller hyperplastic nodules and preneoplastic lesions (30%) in carcinogen and antisense oligomer-treated group as compared with carcinogen control group. Treatment of antisense c-raf.1 oligomers enhanced cytochrome P-450 content (81%) and reduced glutathione S-transferase activity (33%), UDP glucuronosyltransferase activity (74%) and MDA concentration (30%) in carcinogen and antisense oligomer-treated group as compared with carcinogen control animals. The oligomer treatment also resulted in less expression in terms of c-raf.1 expressed lesion count as compared to carcinogen control group.

Conclusion

The study demonstrates that the antisense oligomer targeted against c-raf.1 mRNA inhibits the overexpression of c-raf.1 gene during hepatocellular carcinoma in rats.

Farber E (1991) Hepatocyte proliferation in stepwise development of experimental liver cell cancer. Dig Dis Sci 36:973–978CrossRefPubMed

Pitot HC (1986) Fundamentals of oncology, 3rd edn. Mercel Dekker, New York, p 532

Pitot HC, Sirica AE (1980) The stages of initiation and promotion in hepatocarcinogenesis. Biochem Biophys Acta 605:191–215PubMed

Schulte-Hermann R (1985) Tumor promotion in the liver. Arch Toxicol 57:147–185CrossRefPubMed

Pitot HC, Dragan YP (1991) Facts and theories concerning the mechanisms of carcinogenesis. FASEB J 5:2280–2286PubMed

Klaunig JE, Kamendulis LM (1999) Mechanism of cancer chemoprevention in hepatic carcinogenesis: modulation of focal lesion growth in mice. Toxicol Sci 52:101–106PubMed

Bannasch P (1984) Sequential cellular changes during chemical carcinogenesis. J Cancer Res Clin Oncol 108:11–22CrossRefPubMed

Schulte-Hermann R (1987) Initiation and promotion in hepatocarcinogenesis. Arch Toxicol 60:179–181CrossRefPubMed

Schulte-Hermann R, Bursch W, Grasl-Kraupp B et al (1995) Role of active cell death (apoptosis) in multi-stage carcinogenesis. Toxicol Lett 82:143–148CrossRefPubMed

10.

Farber E, Sarma DS (1987) Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest 56(1):4–22PubMed

11.

Rabes HM (1983) Development and growth of early preneoplastic lesions induced in the liver by chemical carcinogen. J Cancer Res Clin Oncol 106:85–92CrossRefPubMed

12.

Coleman WB (2003) Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3(6):573–588CrossRefPubMed

13.

Kolaja KL, Stevenson DE, Walborg EF Jr et al (1996) Reversibility of promoter induced hepatic focal lesion growth in mice. Carcinogenesis 17(7):1403–1409CrossRefPubMed

14.

Bannasch P (1968) The cytoplasm of hepatocytes during carcinogenesis. Recent Results Cancer Res 19:1–100

15.

Bannasch P, Mayer D, Hacker HJ (1980) Hepatocellular glycogenosis and hepatocarcinogenesis. Biochim Biophys Acta 605:217–245PubMed

16.

Bannasch P, Hacker HJ, Klimek F et al (1984) Hepatocellular glycogenosis and related pattern of enzymatic changes during hepatocarcinogenesis. Adv Enzym Reg 22:97–121CrossRef

17.

Roomi MW, Ho RK, Sarma DSR et al (1985) A common biochemical pattern in preneoplastic hepatocyte nodules generated in four different models in the rat. Cancer Res 45:564–571PubMed

18.

Buchmann A, Schwarz M, Schmitt R et al (1987) Development of cytochrome P-450-altered preneoplastic and neoplastic lesions during nitrosamine-induced hepatocarcinogenesis in the rat. Cancer Res 47:2911–2918PubMed

19.

Lindahl R, Feinstein R (1876) Purification and characterization of aldehyde dehydrogenase from 2-acetylaminofluorene induced rat hepatomas. Biochim Biophys Acta 452:345–355

20.

Levin W, Lu AYH, Thomas PE et al (1978) Identification of epoxide hydrolase in rat liver hyperplastic nodules. Proc Natl Acad Sci USA 75:3240–3243CrossRefPubMed

21.

Satoh K, Kitahara A, Soma Y et al (1985) Purification, induction and distribution of placental glutathione transferase: a new marker enzyme for preneoplastic cells in rat chemical hepatocarcinogenesis. Proc Natl Acad Sci USA 85:3964–3968CrossRef

22.

Sánchez-Pérez Y, Carrasco-Legleu C, García-Cuellar C et al (2005) Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. Cancer Lett 217(1):25–32CrossRefPubMed

23.

Daum G, Eisenmann-Tappe I, Fries HW et al (1994) The ins and outs of Raf kinases. Trends Biochem Sci 19:474–480CrossRefPubMed

24.

Rapp UR (1991) Role of Raf-1 serine/threonine protein kinase in growth factor signal transduction. Oncogene 6:495–500PubMed

25.

Sebolt-Leopold J (2000) Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19:6594–6599CrossRefPubMed

26.

Avruch J, Khokhlatchev A, Kyriakis JM et al (2001) Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56:127–155CrossRefPubMed

27.

Störm SM, Rapp UR (1993) Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67:201–210CrossRefPubMed

28.

Stanton VP Jr, Cooper GM (1987) Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol 7:1171–1179PubMed

29.

Störm SM, Brennscheidt U, Sithanandam G et al (1990) Raf oncogenes in carcinogenesis. Crit Rev Oncog 2:1–8PubMed

30.

Crooke ST (1993) Therapeutic application of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329–376CrossRef

31.

Crooke ST (1999) Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1489:31–44PubMed

32.

Pitot HC, Peraino C, Morse PA Jr, Potter VR (1964) Hepatomas in tissue culture compared with adapting liver in vivo. Natl Cancer Inst Monogr 13:229–245PubMed

33.

Reuber MD (1961) A transplantable bile-secreting hepatocellular carcinoma in the rat. J Natl Cancer Inst 26:891–897PubMed

34.

Mukherjee B, Basu M, Chatterjee M (2001) Effect of selenomethionine on n-methylnitrosoguanidine-induced colonic aberrant crypt foci in rats. Eur J Cancer Prev 10:347–355CrossRefPubMed

35.

Moreno FS, Rizzi MB, Dagli ML et al (1991) Inhibitory effects of β-carotene on preneoplastic lesions induced in Wistar rats by the resistant hepatocyte model. Carcinogenesis 12(10):1817–1822CrossRefPubMed

36.

Bannasch P (1976) Cytology and cytogenesis of neoplastic (hyperplastic) hepatic nodules. Cancer Res 367:2555–2562

37.

Bannasch P, Jahn UR, Hacker HJ et al (1997) Focal hepatic glycogenosis: a putative preneoplastic lesion associated with neoplasia and cirrhosis in explanted human livers. Int J Oncol 10:261–268

38.

Yang D, Alt E, Rogler CE (1993) Coordinate expression of N-myc2 and insulin-like growth factor II in precancerous altered hepatic foci in woodchuck hepatitis virus carriers. Cancer Res 53:2020–2027PubMed

39.

Mukherjee B, Ghosh S, Das T et al (2005) Characterization of insulin-like-growth factor II (IGF II) mRNA positive hepatic altered foci and IGF II expression in hepatocellular carcinoma during diethylnitrosamine-induced hepatocarcinogenesis in rats. J Carcinogenesis 4:12CrossRef

40.

Omura T, Sato N (1964) The carbon monoxide-binding pigment of liver microsome. J Biol Chem 239:2370–2378PubMed

41.

Habig WH, Pabst MI, Jacob WB (1975) Glutathione S-transferase: the first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130–7139

42.

Anderson T, Pesonens M, Johansson C (1985) Differentiatial induction of cytochrome P-450 dependent monoxygenase, epoxide hydrolase, glutathione transferase and UDP-glucuronosyl transferase activities in the liver of the rainbow trout by β-napthoflavone or clophen A 50. Biol Chem Pharmacol 34:3309–3314

43.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin-phenol reagent. J Biol Chem 193:265–275PubMed

44.

Nichans WG, Samuelson B (1968) Formation of MDA from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 6:126–130CrossRef

45.

Braissant O, Wahli W (1998) A simplified in situ hybridization protocol using non-radioactively labeled probes to detect abundant and rare mRNAs on tissue sections. Biochemica 1:10–16

46.

Jasper HG, Brasel A (1980) Rat liver DNA synthesis during the “Catch-up” growth of varied nutritional rehabilitation. J Nutr 110:2336–2340PubMed

47.

Jeffrey WH, Paul JH (1988) Underestimation of DNA synthesis by [3H] thymidine incorporation in marine bacteria. Appl Environ Microbiol 54(12):3165–3168PubMed

48.

Su Q, Benner A, Hofmann WJ et al (1997) Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch 431(6):391–406CrossRefPubMed

49.

Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 11:81–128CrossRefPubMed

50.

Vaca CE, Wilhelm J, Harms-Ringdahl M (1988) Interaction of lipid peroxidation products with DNA. A review. Mutat Res 195:137–149PubMed

51.

Ji C, Rouzer CA, Marnett LJ et al (1998) Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Carcinogenesis 19(7):1275–1283CrossRefPubMed

52.

Barnard DL, Hettich E, Chuang XF et al (1995) Identification of the sites of interaction between c-raf.1 and Ras-GTP. Oncogene 10:1283–1290PubMed

53.

Watkins PB (1992) Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 21:511–526PubMed

54.

Dahm LJ, Jones DP (1996) Mechanisms of chemically induced liver disease. In: Zakin D, Boyer TD (eds) Hepatology: a textbook of liver disease, 3rd edn. Saunders, Philadelphia, pp 875–890

55.

Lee WM (1995) Drug-induced hepatotoxicity. N Engl J Med 333:1118–1127CrossRefPubMed

56.

Bock KW, Lilienblum W, Pfeil H et al (1982) Increased uridine diphosphate-glucuronyltransferase activity in preneoplastic liver nodules and Morris hepatomas. Cancer Res 42:3747–3752PubMed

57.

Tatematsu M, Mera Y, Ito N et al (1985) Relative merits of immunohistochemical demonstrations of placenta, A, B and C forms of glutathione S-transferase and histochemical demonstration of f-glutamyl transferase as markers of altered foci during liver carcinogenesis in rats. Carcinogenesis 6:1621–1626CrossRefPubMed

58.

Bannasch P (1996) Pathogenesis of hepatocellular cacinoma: sequential cellular, molecular, and metabolic changes. In: Boyer JL, Ockner RK (eds) Progress in liver diseases, vol 14. Saunders, Philadelphia, pp 161–197

59.

Hwang Y, Choi J, Kim S et al (2004) Over-expression of c-raf-1 protooncogene in liver cirrhosis and hepatocellular carcinoma. Hepatology Res. 29:113–121CrossRef

60.

Beer DG, Neveu MJ, Paul DL et al (1988) Expression of the c-mf protooncogene, 7-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms. Cancer Res 48:1610–1617PubMed

Titel: Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat
verfasst von: Tanushree Das
Falguni Patra
Biswajit Mukherjee
Publikationsdatum: 01.01.2010
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2010
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1035-4

Springer Medizin

Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences

Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells

The effect of transcatheter arterial chemoembolization on phase II drug metabolism enzymes in patients with hepatocellular carcinoma

Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report

Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie